English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Hyperthermia(HT)has been considered a promising approach in cancer therapy. However, the acquisition of thermoresistance in tumor due to several responses of tumor,such as an increase in heat shock proteins (HSPs),makes HT less effective. The induction of HSPs is mainly mediated by the activation of heat shock transcription factor 1 (HSF1). It has been shown that HSF1 is abundantly expressed in human tumor cells of various origins. Moreover, it takes part in the initiation and maintenance of tumor. Silencing of HSF1 could suppress tumor formation and enhance the effectiveness of HT. In this review,the physiological and pathological roles of HSF1 in cancer cells are summarized, and its potential as a therapeutic target for hyperthermic therapy is discussed.

Can be Heat Shock Transcription Factor 1 a Potential Target for Hyperthermic Therapy?